Early Data From Ionis/Biogen’s BIIB080 Keeps Tau Alzheimer’s Hopes Alive

Unique Antisense Approach To Tau

While many other approaches have failed, Ionis and Biogen hope their novel oligonucleotide can stop toxic tau tangles forming in the brain.

Ionis HQ — Preclinical studies showed BIIB080 could prevent or even reverse Alzheimer's in transgenic mice - but the Phase I study did not examine clinical efficacy in humans.

While controversy around the US approval of Biogen’s beta-amyloid targeting Aduhelm rumbles on, its partner Ionis Pharmaceuticals has produced positive early-stage data from another Alzheimer’s candidate this time targeting tau, BIIB080.

Alongside beta amyloid, tau is the other key protein implicated in the disease, but over the years has seen similarly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

11 Jun 2025

• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

11 Jun 2025

• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

11 Jun 2025

• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.